TapImmune Announces Agreement With AppTec FDA Registered Facility to Begin Testing on Company’s Novel Cancer Vaccine

TapImmune a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced a contractual agreement with AppTec, headquartered in St. Paul, Minnesota, for the preclinical testing of its lead product.
TapImmune